The summer school holidays might be done and dusted, but that doesn't mean you have to return to your 9-5 just yet.

What do the analysts say? Following the release of the quarterly report, Bank of America cut its price target for Teva from ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report)’s share price was down 4.6% on Thursday after UBS Group lowered their price target on the stock from $30.00 to $27.00. UBS Group ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

BofA Securities made adjustments to its financial model for Teva Pharmaceutical Industries Ltd (NYSE:TEVA), resulting in a lowered price target. While the firm maintained a Buy rating on the stock, ...